Increased risk of lymphoproliferative disorders following the use of OKT3: Association with cumulative dose

  • Lode J. Swinnen
Part of the Transplantation and Clinical Immunology book series (TRAC, volume 27)


Post-transplantation lymphoproliferative disorder (PTLD) is a frequently fatal complication of immunosuppression [1]. The term describes Epstein–Barr virus associated B-lymphoproliferations occurring after organ transplantation. The disease has assumed increasing clinical importance in view of the constantly rising number of organ transplant recipients and the development of highly potent and specific immunosuppressive drugs. Continued, uncontrolled EBV-driven proliferation of B-cells in the absence of adequate T-cell control has been proposed as a mechanism for the development of PTLD by Klein and others [2, 3]. As proliferation continues, clones with a growth advantage emerge, and a monoclonal population eventually predominates. This model is capable of at least partially explaining many of the otherwise puzzling clinical and pathologic features of this disease.


Lymphoproliferative Disorder Rejection Episode Organ Transplant Recipient Acute Cardiac Allograft Rejection Prophylactic OKT3 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Nalesnik MA, Makowka L, Starzl TE. The diagnosis and treatment of posttransplant lymphoproliferative disorders. Current Problems In Surgery 1988; 25: 367–472.PubMedCrossRefGoogle Scholar
  2. 2.
    Purtilo DT. Epstein-Barr-virus-induced oncogenesis in immune-deficient individuals. Lancet 1980; 1: 300–303.PubMedCrossRefGoogle Scholar
  3. 3.
    Klein G. Lymphoma development in mice and humans: diversity of initiation is followed by convergent cytogenetic evolution. Proceedings of the National Academy of Sciences of the United States of America 1979; 76: 2442–2446.PubMedCrossRefGoogle Scholar
  4. 4.
    Armitage JM, Kormos RL, Stuart RS et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. Journal of Heart & Lung Transplantation 1991; 10: 877–886.Google Scholar
  5. 5.
    Starzl TE, Nalesnik MA, Porter KA et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583–587.PubMedCrossRefGoogle Scholar
  6. 6.
    Beveridge T, Krupp P, McKibbin C. Lymphomas and lymphoproliferative lesions developing under cyclosporin therapy [letter]. Lancet 1984; 1: 788.PubMedCrossRefGoogle Scholar
  7. 7.
    Penn I. Malignant lymphomas in organ transplant recipients. Transplantation Proceedings 1981; 13: 736–738.PubMedGoogle Scholar
  8. 8.
    Cleary ML, Warnke R, Sklar J. Monoclonality of lymphoproliferative lesions in cardiactransplant recipients. Clonal analysis based on immunoglobulin-gene rearrangements. New England Journal of Medicine 1984; 310: 477–482.PubMedCrossRefGoogle Scholar
  9. 9.
    Nalesnik MA, Jaffe R, Starzl TE et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. American Journal of Pathology 1988; 133: 173–192.PubMedGoogle Scholar
  10. 10.
    Bach JF, Chatenoud L. Immunologic monitoring of Orthoclone OKT3-treated patients: the problem of antimonoclonal immune response. Transplantation Proceedings 1987; 19: 17–20.PubMedGoogle Scholar
  11. 11.
    Costanzo-Nordin MR, Silver MA, O’Connell JB et al. Successful reversal of acute cardiac allograft rejection with OKT monoclonal antibody. Circulation 1987; 76: V71-V80.PubMedGoogle Scholar
  12. 12.
    Renlund DG, O’Connell JB, Gilbert EM et al. A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Decreased rejection and less corticosteroid use with OKT3. Transplantation 1989; 47: 599–605.PubMedCrossRefGoogle Scholar
  13. 13.
    Barr ML, Sanchez JA, Seche LA, Schulman LL, Smith CR, Rose EA. Anti-CD3 monoclonal antibody induction therapy. Immunological equivalency with triple-drug therapy in heart transplantation. Circulation 1990; 82: IV291-IV294.PubMedGoogle Scholar
  14. 14.
    Witherspoon RP, Fisher LD, Schoch G et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia [see comments]. New England Journal of Medicine 1989; 321: 784–789.PubMedCrossRefGoogle Scholar
  15. 15.
    Swinnen LJ, Costanzo-Nordin MR, Fisher SG et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. New England Journal of Medicine 1990; 323: 1723–1728.PubMedCrossRefGoogle Scholar
  16. 16.
    Billingham ME. Some recent advances in cardiac pathology. Human Pathology 1979; 10: 367–386.PubMedCrossRefGoogle Scholar
  17. National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin’s Lymphoma Pathologic Classification Project. Cancer 1982; 49: 2112–2135.Google Scholar
  18. 18.
    Ho M, Miller G, Atchison RW et al. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. Journal of Infectious Diseases 1985; 152: 876–886.PubMedCrossRefGoogle Scholar
  19. 19.
    Swinnen LJ, Fisher SG, Fisher RI, Koch D, Costanzo MR. Elimination Of OKT3 Induction Therapy: Impact On The Incidence Of Lymphoma Following Cardiac Transplantation. J Heart Lung Transplant 1994; 13 No. 1(2)(abs 148): S68 (abstract).Google Scholar
  20. 20.
    Swinnen LJ, Fisher RI. OKT3 monoclonal antibodies induce interleukin-6 and interleukin-10: a possible cause of lymphoproliferative disorders associated with transplantation. [Review]. Current Opinion in Nephrology & Hypertension 1993; 2: 670–678.Google Scholar
  21. 21.
    Zutter MM, Martin PJ, Sale GE et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72: 520–529.PubMedGoogle Scholar
  22. 22.
    Shapiro RS, McClain K, Frizzera G et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71: 1234–1243.PubMedGoogle Scholar
  23. 23.
    Alfrey EJ, Friedman AL, Grossman RA et al. A recent decrease in the time to development of monomorphous and polymorphous posttransplant lymphoproliferative disorder Transplantation 1992; 54: 250–253.Google Scholar
  24. 24.
    Cockfield SM, Preiksaitis J, Harvey E et al. Is sequential use of ALG and OKT3 in renal transplants associated with an increased incidence of fulminant posttransplant lymphoproliferative disorder? Transplantation Proceedings 1991; 23: 1106–1107.PubMedGoogle Scholar
  25. 25.
    Renard TH, Andrews WS, Foster ME. Relationship between OKT3 administration, EBV seroconversion, and the lymphoproliferative syndrome in pediatric liver transplant recipients. Transplantation Proceedings 1991; 23: 1473–1476.PubMedGoogle Scholar
  26. 26.
    Rosenthal JT, Wilkinson AH, Canfield CW. Fulminant Epstein-Barr Virus-Associated Post-Transplant lymphoproliferative Disorders Following OKT3 Therapy. ASTP Annual Meeting 1991; 74 (abs).Google Scholar
  27. 27.
    Rinde-Hoffman D, Cintron GB, Ferguson JE, Toole JC, Bugni WB. Lymphoproliferative disorder early after cardiac transplantation [published erratum appears in Am J Cardiol 1992 Mar 15; 69(8): 844]. American Journal of Cardiology 1991; 68: 1724–1725.PubMedCrossRefGoogle Scholar
  28. 28.
    Penn I. The changing pattern of posttransplant malignancies. Transplantation Proceedings 1991;23: 1101–1103.PubMedGoogle Scholar
  29. 29.
    Ren EC, Chan SH. Possible enhancement of Epstein-Barr virus infections by the use of OKT3 in transplant recipients. Transplantation 1988; 45: 988–989.PubMedCrossRefGoogle Scholar
  30. 30.
    Bird AG, McLachlan SM, Britton S. Cyclosporin A promotes spontaneous outgrowth in vitro of Epstein-Barr virus-induced B-cell lines. Nature 1981; 289: 300–301.PubMedCrossRefGoogle Scholar
  31. 31.
    Emery RW, Lake KD. Post-transplantation Lymphoproliferative Disorder and OKT3 (let.). N Engl J Med 1991; 324: 1437.CrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Lode J. Swinnen

There are no affiliations available

Personalised recommendations